| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10910973 | Lung Cancer | 2015 | 8 Pages |
Abstract
DB and SB produced modest PFS benefits in the second-line treatment of patients with advanced non-Sq NSCLC. Because of the toxicity of DB and the low response rate of SB, neither regimen warrants further investigation, excluding DB in bevacizumab-naïve patients with advanced non-Sq NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kazumi Nishino, Fumio Imamura, Toru Kumagai, Nobuyuki Katakami, Akito Hata, Chiyuki Okuda, Yoshiko Urata, Yosihihiro Hattori, Motoko Tachihara, Souichirou Yokota, Takashi Nishimura, Toshihiko Kaneda, Miyako Satouchi, Satoshi Morita, Shunichi Negoro,